CRNX CRINETICS PHARMACEUTICALS IN
2026Q1 · CUSIP 22663K107 · Sector: Healthcare & Biotech
Neutral · No signal
Holders
242
Δ holders QoQ
+1
Breadth percentile
Top 58%
Whale holders
136
Δ whales
+3
Inst. holding value
$4.4B
New positions
47
Closed positions
46
Price momentum (1Q)
-20.6%
Put / Call
3/4
Breadth history (34 quarters)
Past Lit Events & Aftermath 7 lit events
| Period | Percentile | Next-1Q return | Next-2Q return |
|---|---|---|---|
| 2024Q2 | Top 7% | +15.6% | -29.1% |
| 2024Q1 | Top 13% | +3.0% | +6.5% |
| 2023Q3 | Top 4% | +32.0% | +78.6% |
| 2023Q2 | Top 19% | +76.1% | +126.9% |
| 2022Q3 | Top 13% | +14.1% | +22.6% |
| 2021Q3 | Top 18% | -27.3% | -27.8% |
| 2020Q2 | Top 15% | -19.0% | -0.9% |
Options Sentiment
Put holders
3
QoQ: -3
Call holders
4
QoQ: -1
See methodology →
Fundamentals
PE (TTM)
—
EPS (TTM)
$-5.14
EPS YoY
—
Revenue (TTM)
$0.0B
Revenue YoY
+2277.5%
Quarterly Revenue & EPS (4Y)
Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable
As of 2026-03-31 · SEC filings (XBRL)